The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Colufase     [2-[(5-nitro-1,3-thiazol-2...

Synonyms: Taenitaz, Cryptaz, Heliton, Alinia, Fental, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Fental

  • Effect of nitazoxanide on morbidity and mortality in Zambian children with cryptosporidiosis: a randomised controlled trial [1].
  • METHODS: Children with cryptosporidial diarrhoea who were admitted to the University Teaching Hospital, Lusaka, Zambia, between November, 2000, and July, 2001, and whose parents consented to their having an HIV test were randomly assigned nitazoxanide (100 mg twice daily orally for 3 days) or placebo [1].
  • In vitro and in vivo activities of nitazoxanide against Clostridium difficile [2].
  • Nitazoxanide (NTZ) is a redox-active nitrothiazolyl-salicylamide prodrug that kills Helicobacter pylori and also many anaerobic bacterial, protozoan, and helminthic species [3].
  • This suggests that nitazoxanide may be effective in treating microsporidiosis caused by E. bieneusi, a disease for which there is no established treatment [4].

High impact information on Fental


Chemical compound and disease context of Fental


Biological context of Fental


Anatomical context of Fental


Associations of Fental with other chemical compounds


Gene context of Fental

  • The rate of improvement was markedly higher in patients with CD4 counts under 50 cells/microL receiving nitazoxanide (P = 0.007) [25].

Analytical, diagnostic and therapeutic context of Fental


  1. Effect of nitazoxanide on morbidity and mortality in Zambian children with cryptosporidiosis: a randomised controlled trial. Amadi, B., Mwiya, M., Musuku, J., Watuka, A., Sianongo, S., Ayoub, A., Kelly, P. Lancet (2002) [Pubmed]
  2. In vitro and in vivo activities of nitazoxanide against Clostridium difficile. McVay, C.S., Rolfe, R.D. Antimicrob. Agents Chemother. (2000) [Pubmed]
  3. Enzymes associated with reductive activation and action of nitazoxanide, nitrofurans, and metronidazole in Helicobacter pylori. Sisson, G., Goodwin, A., Raudonikiene, A., Hughes, N.J., Mukhopadhyay, A.K., Berg, D.E., Hoffman, P.S. Antimicrob. Agents Chemother. (2002) [Pubmed]
  4. Successful treatment with nitazoxanide of Enterocytozoon bieneusi microsporidiosis in a patient with AIDS. Bicart-Sée, A., Massip, P., Linas, M.D., Datry, A. Antimicrob. Agents Chemother. (2000) [Pubmed]
  5. In vitro activities of itraconazole, methiazole, and nitazoxanide versus Echinococcus multilocularis larvae. Reuter, S., Manfras, B., Merkle, M., Härter, G., Kern, P. Antimicrob. Agents Chemother. (2006) [Pubmed]
  6. Application of quantitative real-time reverse transcription-PCR in assessing drug efficacy against the intracellular pathogen Cryptosporidium parvum in vitro. Cai, X., Woods, K.M., Upton, S.J., Zhu, G. Antimicrob. Agents Chemother. (2005) [Pubmed]
  7. Inhibitory activities of epidermal growth factor receptor tyrosine kinase-targeted dihydroxyisoflavone and trihydroxydeoxybenzoin derivatives on Sarcocystis neurona, Neospora caninum, and Cryptosporidium parvum development. Gargala, G., Baishanbo, A., Favennec, L., François, A., Ballet, J.J., Rossignol, J.F. Antimicrob. Agents Chemother. (2005) [Pubmed]
  8. Nitazoxanide, a potential drug for eradication of Helicobacter pylori with no cross-resistance to metronidazole. Mégraud, F., Occhialini, A., Rossignol, J.F. Antimicrob. Agents Chemother. (1998) [Pubmed]
  9. Randomized clinical study of nitazoxanide compared to metronidazole in the treatment of symptomatic giardiasis in children from Northern Peru. Ortiz, J.J., Ayoub, A., Gargala, G., Chegne, N.L., Favennec, L. Aliment. Pharmacol. Ther. (2001) [Pubmed]
  10. Efficacy of nitazoxanide and paromomycin in biliary tract cryptosporidiosis in an immunosuppressed gerbil model. Baishanbo, A., Gargala, G., Duclos, C., François, A., Rossignol, J.F., Ballet, J.J., Favennec, L. J. Antimicrob. Chemother. (2006) [Pubmed]
  11. Successful treatment of metronidazole- and albendazole-resistant giardiasis with nitazoxanide in a patient with acquired immunodeficiency syndrome. Abboud, P., Lemée, V., Gargala, G., Brasseur, P., Ballet, J.J., Borsa-Lebas, F., Caron, F., Favennec, L. Clin. Infect. Dis. (2001) [Pubmed]
  12. Efficacy of treatment with paromomycin, azithromycin, and nitazoxanide in a patient with disseminated cryptosporidiosis. Giacometti, A., Burzacchini, F., Cirioni, O., Barchiesi, F., Dini, M., Scalise, G. Eur. J. Clin. Microbiol. Infect. Dis. (1999) [Pubmed]
  13. Epidemiology and control of intestinal parasites with nitazoxanide in children in Mexico. Diaz, E., Mondragon, J., Ramirez, E., Bernal, R. Am. J. Trop. Med. Hyg. (2003) [Pubmed]
  14. Nitazoxanide in the treatment of cryptosporidial diarrhea and other intestinal parasitic infections associated with acquired immunodeficiency syndrome in tropical Africa. Doumbo, O., Rossignol, J.F., Pichard, E., Traore, H.A., Dembele, T.M., Diakite, M., Traore, F., Diallo, D.A. Am. J. Trop. Med. Hyg. (1997) [Pubmed]
  15. Pharmacokinetics of nitazoxanide after single oral dose administration in 6 healthy volunteers. Stockis, A., Deroubaix, X., Lins, R., Jeanbaptiste, B., Calderon, P., Rossignol, J.F. International journal of clinical pharmacology and therapeutics. (1996) [Pubmed]
  16. In vitro effect of nitazoxanide against Entamoeba histolytica, Giardia intestinalis and Trichomonas vaginalis trophozoites. Cedillo-Rivera, R., Chávez, B., González-Robles, A., Tapia, A., Yépez-Mulia, L. J. Eukaryot. Microbiol. (2002) [Pubmed]
  17. Nitazoxanide treatment for giardiasis and cryptosporidiosis in children. Bailey, J.M., Erramouspe, J. The Annals of pharmacotherapy. (2004) [Pubmed]
  18. Experimental infection of cats with Tritrichomonas foetus. Gookin, J.L., Levy, M.G., Law, J.M., Papich, M.G., Poore, M.F., Breitschwerdt, E.B. Am. J. Vet. Res. (2001) [Pubmed]
  19. Use of nitazoxanide for gastrointestinal tract infections: treatment of protozoan parasitic infection and beyond. Bobak, D.A. Current infectious disease reports. (2006) [Pubmed]
  20. In vitro evaluation of activities of nitazoxanide and tizoxanide against anaerobes and aerobic organisms. Dubreuil, L., Houcke, I., Mouton, Y., Rossignol, J.F. Antimicrob. Agents Chemother. (1996) [Pubmed]
  21. Activity of nitazoxanide alone and in combination with azithromycin and rifabutin against Cryptosporidium parvum in cell culture. Giacometti, A., Cirioni, O., Barchiesi, F., Ancarani, F., Scalise, G. J. Antimicrob. Chemother. (2000) [Pubmed]
  22. In vitro effects of nitazoxanide on Echinococcus granulosus protoscoleces and metacestodes. Walker, M., Rossignol, J.F., Torgerson, P., Hemphill, A. J. Antimicrob. Chemother. (2004) [Pubmed]
  23. Nitazoxanide for the treatment of Clostridium difficile colitis. Musher, D.M., Logan, N., Hamill, R.J., Dupont, H.L., Lentnek, A., Gupta, A., Rossignol, J.F. Clin. Infect. Dis. (2006) [Pubmed]
  24. Treatment options for the eradication of intestinal protozoa. Farthing, M.J. Nature clinical practice. Gastroenterology & hepatology. (2006) [Pubmed]
  25. Nitazoxanide for persistent diarrhoea in Zambian acquired immune deficiency syndrome patients: a randomized-controlled trial. Zulu, I., Kelly, P., Njobvu, L., Sianongo, S., Kaonga, K., McDonald, V., Farthing, M., Pollok, R. Aliment. Pharmacol. Ther. (2005) [Pubmed]
  26. Efficacy of nitazoxanide against Cryptosporidium parvum in cell culture and in animal models. Theodos, C.M., Griffiths, J.K., D'Onfro, J., Fairfield, A., Tzipori, S. Antimicrob. Agents Chemother. (1998) [Pubmed]
  27. Secondary and primary murine alveolar echinococcosis: combined albendazole/nitazoxanide chemotherapy exhibits profound anti-parasitic activity. Stettler, M., Rossignol, J.F., Fink, R., Walker, M., Gottstein, B., Merli, M., Theurillat, R., Thormann, W., Dricot, E., Segers, R., Hemphill, A. Int. J. Parasitol. (2004) [Pubmed]
WikiGenes - Universities